Andrei Baciu: Minimum 3,128,000 anti-COVID vaccine doses to arrive in April
Secretary of State with the Health Ministry Andrei Baciu states that, according to the delivery schedule, 2.6 million anti-COVID vaccine doses will arrive in Romania in March, and at least 3,128,000 doses in April. "Regarding the vaccine doses that will arrive in the next period, until the end of March (...) we have a total of over 2.6 million vaccine doses. I will only mention the total for each type of vaccine. Thus, for the vaccine produced by BioNTech-Pfizer - 1,112,000, for the one produced by Moderna - 268,000 and for the one produced by AstraZeneca - 1,300,000 doses for March," Baciu told a Tuesday's press conference at Victoria Palace. He added that, for April, Romania will receive a minimum of 3,128,000 vaccine doses from Pfizer, Moderna and AstraZeneca. "We will receive the vaccine produced by BioNTech-Pfizer in several batches. 2,111,000 (...) 527,000 doses in four batches. For the vaccine produced by Moderna we will have a minimum of 249,000 or a maximum of 333,000, we will see the final figure in the next period. Anyway, there will be two batches, the same as so far. The doses will be delivered every two weeks, so we are talking about a minimum of 103,000 in the second week, with a maximum possible of 129,000. In the last week we will receive a minimum of 146,000 or, we hope, up to a maximum of 204,000. As for the vaccine produced by AstraZeneca, we also have an estimate, a minimum of 766,000, up to a maximum of 976,000. Basically, if we take into account the minimum amounts from the two companies, cumulated with what we know from BioNTech Pfizer, we are talking about 3,128,000 vaccines for the month of April", the secretary of state explained. Andrei Baciu added that, in the event that Johnson&Johnson also receives a positive recommendation, the doses that this company will send will be added to the total. AGERPRES (RO - author: Daniel Florea, editor: Catalin Alexandru; EN - author: Bogdan Gabaroi; editor: Adina Panaitescu)
- Log in to post comments